Mostrar el registro sencillo del ítem
dc.contributor.author | García Iglesias, Cristina | |
dc.contributor.author | Puledda, Francesca | |
dc.contributor.author | Echavarría Íñiguez, Ana | |
dc.contributor.author | González Osorio, Yesica | |
dc.contributor.author | Sierra Mencía, Álvaro | |
dc.contributor.author | Recio García, Andrea | |
dc.contributor.author | González Celestino, Ana | |
dc.contributor.author | Valle Peñacoba, Gonzalo | |
dc.contributor.author | Irimia, Pablo | |
dc.contributor.author | Guerrero Peral, Angel Luis | |
dc.contributor.author | García Azorín, David | |
dc.date.accessioned | 2024-09-03T11:56:36Z | |
dc.date.available | 2024-09-03T11:56:36Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Journal of Clinical Medicine, 2023, Vol. 12, Nº. 1, 122 | es |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/69587 | |
dc.description | Producción Científica | es |
dc.description.abstract | Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT 05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients. The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study. Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters’ diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients. The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9–25%. The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Headache | es |
dc.subject | Cefalea | es |
dc.subject | Headache - Treatment | es |
dc.subject | Cefalea - Tratamiento | es |
dc.subject | Head - Diseases | es |
dc.subject | Cabeza - Enfermedades | es |
dc.subject | Nervous system - Diseases - Treatment | es |
dc.subject | Nervioso, Sistema - Enfermedades - Tratamiento | es |
dc.subject | Medicine | es |
dc.subject | Neurology | es |
dc.title | Treatment of primary nummular headache: a series of 183 patients from the NUMITOR study | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2022 The authors | es |
dc.identifier.doi | 10.3390/jcm12010122 | es |
dc.relation.publisherversion | https://www.mdpi.com/2077-0383/12/1/122 | es |
dc.identifier.publicationfirstpage | 122 | es |
dc.identifier.publicationissue | 1 | es |
dc.identifier.publicationtitle | Journal of Clinical Medicine | es |
dc.identifier.publicationvolume | 12 | es |
dc.peerreviewed | SI | es |
dc.description.project | Junta de Castilla y León, Gerencia Regional de Salud (SACYL) - (grant GRS 2416/A/21) | es |
dc.identifier.essn | 2077-0383 | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
dc.subject.unesco | 32 Ciencias Médicas | es |
dc.subject.unesco | 3205.07 Neurología | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
![Atribución 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-by.png)